1633-41-6

Basic information

• Product Name: 4-(METHYLAMINO)-3-NITROPYRIDINE
• Synonyms: 4-(METHYLAMINO)-3-NITROPYRIDINE;UKRORGSYN-BB BBV-213844
• CAS NO: 1633-41-6
• Molecular Formula: C₆H₇N₃O₂
• Molecular Weight: 153.14
• Product Categories: Heterocycle-Pyridine series
• Mol File: 1633-41-6.mol
• Article Data: 19

Chemical Properties

• Melting Point: 163 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• Boiling Point: 299.5°C at 760 mmHg
• Flash Point: 134.9°C
• Appearance: /
• Density: 1.343g/cm³
• Vapor Pressure: 0.00119mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.53±0.18(Predicted)
• CAS DataBase Reference: 4-(METHYLAMINO)-3-NITROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(METHYLAMINO)-3-NITROPYRIDINE(1633-41-6)
• EPA Substance Registry System: 4-(METHYLAMINO)-3-NITROPYRIDINE(1633-41-6)

Safety Data

• Hazardous Substances Data: 1633-41-6(Hazardous Substances Data)

Usage

General Description

4-(Methylamino)-3-nitropyridine is a chemical compound with the molecular formula C6H7N3O2. It is a nitropyridine derivative with a methylamino group attached to the fourth carbon atom of the pyridine ring. 4-(METHYLAMINO)-3-NITROPYRIDINE is used in the synthesis of pharmaceuticals, agrochemicals, and dyes. It has also been studied for its potential use in organic electronic materials. 4-(Methylamino)-3-nitropyridine is known for its moderate toxicity and should be handled with care. Its properties and uses make it a valuable compound in various industrial and research applications.

InChI:InChI=1/C6H7N3O2/c1-7-5-2-3-8-4-6(5)9(10)11/h2-4H,1H3,(H,7,8)

Upstream product

• 13091-23-1 4-chloro-3-nitropyridine 
• 74-89-5 methylamine 
• 27256-89-9 N-methyl-N-(4-pyridyl)-nitramine 
• 31872-62-5 4-methoxy-3-nitro-pyridine 
• 1796-84-5 4-ethoxy-3-nitropyridine 
• 1121-58-0 4-(Methylamino)pyridine 
• 27256-90-2 1,4-dihydro-1-methyl-4-nitriminopyridine 

Downstream Products

• 57680-52-1 spinaceamine 
• 1839-17-4 3-amino-4-(methylamino)pyridine 
• 104503-82-4 4-N-methylnitramino-3-nitropyridine 
• 50432-67-2 6-chloro-N₄-methyl-4,5-pyridinediamine 
• 1207455-23-9 ethyl 2-(4-fluorophenyl)-3-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1207455-22-8 8-(4-fluorophenyl)-9-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 675581-77-8 2-ethyl-1-methyl-1H-imidazo[4,5-c]pyridine 
• 5028-32-0 1-methylimidazo<4,5-c>pyridine 
• 45880-13-5 1,2-dimethylimidazo<4,5-c>pyridine 
• 50432-68-3 4-chloro-1-methyl-1H-imidazo(4,5-c)pyridine 
• 496955-69-2 benzyl-(1-methyl-2-([1,2,3]triazol-2-yl)-1H-imidazo[4,5-c]pyridin-4-yl)amine 

Relevant articles and documents

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 may have the meanings given in claim 1, as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.